Oncology PracticeReal-world data for immunotherapy-treated NSCLC found robustJuly 29, 2019Lung CancerImmuno-oncology
Oncology PracticeStudy outlines survival factors with nivolumabJuly 25, 2019Lung CancerRenal Cell CarcinomaMelanomaImmuno-oncology
Oncology PracticeDurvalumab fails to advance in pancreatic cancerJuly 24, 2019GastroenterologyImmuno-oncologyGastrointestinal Cancer
Oncology PracticeIL-6, CRP are prognostic for checkpoint inhibition in melanomaJuly 19, 2019MelanomaImmuno-oncology
Hematology NewsBispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomasJune 21, 2019Aggressive LymphomasImmunotherapyLymphoma & Plasma Cell DisordersImmuno-oncologyLeukemia, Myelodysplasia, TransplantationB Cell LymphomaMantle Cell Lymphoma
Oncology PracticeAPHINITY trial: Biomarker analysis IDs predictive, prognostic factorsJune 21, 2019Breast CancerImmuno-oncology
Chemo-free neoadjuvant approaches emerge in NSCLC and breast cancerJune 21, 2019Lung CancerBreast CancerImmuno-oncology
Oncology PracticeNiraparib-pembrolizumab combo finds niche in breast, ovarian cancersJune 17, 2019Gynecologic CancerBreast CancerImmuno-oncology
Oncology PracticeSkin plus GI adverse events with checkpoint inhibitors linked to risk of additional adverse eventsJune 14, 2019Immuno-oncologyImmunotherapy
Oncology PracticeEULAR issues guidelines on managing rheumatic complications of cancer immunotherapiesJune 14, 2019Immuno-oncologyImmunotherapy
Oncology PracticeAdding ipilimumab to nivolumab provides no benefit in SCC trialJune 12, 2019Lung CancerImmuno-oncology
Oncology PracticeAdjuvant immunotherapy results ‘encouraging’ in early NSCLCJune 11, 2019Lung CancerImmunotherapyImmuno-oncology
Oncology PracticeCheckpoint inhibitor rechallenge is possible for select patientsJune 6, 2019Immuno-oncologyImmunotherapyLung Cancer
